Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 11/20 | 0.54 |
| ▸ | BACE1 | P56817 | 8/20 | 0.54 |
| ▸ | DNMT3A | Q9Y6K1 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.48 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.46 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2179908 | 0.91 | ACHE (0.54) | ACHEBACE1DNMT3AMKNK1KDM1A | |
| SCHEMBL2179121 | 0.87 | IKBKB (0.53) | MAPK1CCNA2CDK2MAPK3MKNK1 | |
| SCHEMBL2678668 | 0.83 | ACHE (0.54) | ACHEBACE1DNMT3AEHMT2 | |
| SCHEMBL2179310 | 0.82 | MKNK1 (0.44) | MAPK1CCNA2CDK2MAPK3MKNK1 | |
| SCHEMBL6128569 | 0.81 | ACHE (0.52) | ACHEBACE1DNMT3AEHMT2 | |
| SCHEMBL2178166 | 0.81 | DYRK1A (0.52) | MKNK1MTORSMG1 | |
| SCHEMBL2181328 | 0.80 | MKNK1 (0.44) | MAPK1CCNA2CDK2MAPK3MKNK1 | |
| SCHEMBL2177558 | 0.80 | ACHE (0.51) | ACHEBACE1DNMT3AEHMT2 | |
| SCHEMBL2179083 | 0.80 | MTOR (0.52) | MKNK1MTORSMG1 | |
| SCHEMBL2179063 | 0.79 | DYRK1A (0.53) | MKNK1MTORSMG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173808-B2 | Substituted naphthalenyl-pyrimidine compounds | ARQULE, INC. (US) | 2012-05-08 | — | — | US | claimed |
| US-8173808-B2 | Substituted naphthalenyl-pyrimidine compounds | ARQULE, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173808-B2 | Substituted naphthalenyl-pyrimidine compounds | ARQULE, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| WO-2011082268-A2 | SUBSTITUTED NAPHTHALENYL-PYRIMIDINE COMPOUNDS | ARQULE INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20110166137-A1 | Substituted Naphthalenyl-Pyrimidine Compounds | ARQULE, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166137-A1 | Substituted Naphthalenyl-Pyrimidine Compounds | ARQULE, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166137-A1 | Substituted Naphthalenyl-Pyrimidine Compounds | DPYD, TP53, TYMP | ACHE 4443/4885BACE1 3159/4885DNMT3A 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.